Clay Thorp - 21 Dec 2022 Form 4 Insider Report for Clearside Biomedical, Inc. (CLSD)

Role
Director
Signature
/s/ Mark Ballantyne, Attorney-in-Fact for Clay Thorp
Issuer symbol
CLSD
Transactions as of
21 Dec 2022
Net transactions value
+$14,266
Form type
4
Filing time
21 Dec 2022, 15:26:40 UTC
Previous filing
19 Dec 2022
Next filing
19 May 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CLSD Common Stock Purchase $14,266 +14,000 +85% $1.02 30,522 21 Dec 2022 Direct
holding CLSD Common Stock 3,545,040 21 Dec 2022 See footnote F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Reporting Person is one of the general partners of: (i) Hatteras Venture Advisors III, LLC, the general partner of HVP III and HVA III; (ii) Hatteras Venture Advisors IV SBIC, LLC, the general partner of HVP IV SBIC; and (iii) Hatteras Venture Advisors IV, LLC, the general partner of Hatteras Venture Partners IV, LP ("HVP IV") and Hatteras NC Fund, LP ("Hatteras NC"). HVP III, HVA III, HVP IV SBIC, HVP IV and Hatteras NC are the record holders of the securities, and the reporting person may be deemed to share voting and dispositive power over the securities held by HVP III, HVA III, HVP IV SBIC, HVP IV and Hatteras NC.
F2 The Reporting Person disclaims beneficial ownership of these securities and this report is not an admission that the reporting person is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.